Aired 3 months ago 4:05
Your Health First with Dr. Galati | KTRH
How Gut Bacteria May Be Linked to Lupus
From the news
Aired 8 months ago 19:37
Bringing Real-World Monitoring to Autoimmune Disease
DxTerity is a genomics company that’s providing real-world monitoring of patients with autoimmune disease with from-home RNA testing to improving the management of these conditions. The company’s technology not only has the potential to change the way diseases such as multiple sclerosis, lupus, and rheumatoid arthritis are managed, but change the way clinical trials in these conditions are conducted. We spoke to Bob Terbrueggen, CEO of DxTerity, about the company’s from-home RNA tests, how they work, and the potential application of the technology.
The Bio Report
Aired 8 months ago 6:24
Who owns genetic testing results?
DNA and genetic testing are big business. But there are real questions about privacy and about what happens to your genetic information after you get tested. Recently, the DNA testing company 23andMe partnered with pharmaceutical giant GlaxoSmithKline to develop personalized drugs and research treatment for diseases like lupus and Parkinson's. Jen King is director of consumer privacy at the Center for Internet and Society at Stanford Law School. King told Marketplace Tech's Molly Wood that, surprisingly, most people who take DNA tests don't think the data is all that personal. (10/16/18)
Marketplace Tech with Molly Wood
Aired 3 months ago 11:25
Hydralazine Pharmacology Hydralazine works as a direct vasodilator. It primarily works on the arterioles versus the venous system. Hydralazine can cause a unique adverse reaction. It can cause a Lupus type syndrome that can result in fever, myopathy and symptoms that mimic arthritis. I discuss drug interactions with hydralazine and how you need to be aware of certain medications that can have additive effects and also those that can oppose the effects of the drug. One of the downsides to using hydralazine is that patients don't like to take it as often as it requires. It is typically dosed three to four times per day. Orthostasis is a risk with any drug that reduces blood pressure and hydralazine is no different.
Real Life Pharmacology - Pharmacology Education for Health Care Professionals